SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2794Bortezomib Sensitizes Human Head and Neck Carcinoma Cells SQ20B to Radiation. CIcebrg-1/17/2007
2793[Targeting aurora kinases as therapy in multiple myeloma] >> Blood. 2007 tuck-1/12/2007
2792[Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathologituck-1/12/2007
2791Banc of America analyst David Witzke was less enthusiastic about Cambridge, MassIcebrg-1/9/2007
2790Merrill, maintains neutral- though they actually sound rather more pessimistic ttom pope-1/8/2007
2789Millennium Pharmaceuticals "underperform," target price reduced SaturIcebrg-1/8/2007
2788Mutliple Myeloma Update from the American Society of Hematology (ASH) - 12/18/0Icebrg-1/7/2007
2787Millennium Achieves 2006 Non-GAAP Profitability, Reduces GAAP Net Loss Thursday Icebrg-1/4/2007
2786Importance of the Different Proteolytic Sites of the Proteasome and the EfficacyIcebrg-1/1/2007
2785Importance of the Different Proteolytic Sites of the Proteasome and the EfficacyIcebrg-1/1/2007
2784Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses Icebrg-1/1/2007
2783Neuroblastoma Tumors Tahira Khan*, Jimmy K. Stauffer*, Rebecca Williams*, Julie Icebrg-1/1/2007
2782Listening to the Patriots (american football for you ex-US types) game on the rarkrw-12/31/2006
2781Top Picks 2007: Ryan Detrick bets on the Millennium [14 out of 14 is not bad atIcebrg-12/31/2006
2780[Comparison of biochemical and biological effects of ML858 (salinosporamide A) atuck-12/22/2006
2779Strange behaviour of company directors - cashing out instead of in. Two of the Icebrg-12/15/2006
2778Form 8-K for MILLENNIUM PHARMACEUTICALS INC 14-Dec-2006 [Judging from the amendIcebrg-12/14/2006
2777Dr. Bob Tepper, President of R&D, to Leave Millennium Thursday December 14, Icebrg-12/14/2006
2776VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical PracticIcebrg-12/12/2006
2775VELCADE(R) (Bortezomib) for Injection Based Therapies Show Consistently High ComIcebrg-12/12/2006
2774VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across RIcebrg-12/11/2006
2773Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for InIcebrg-12/11/2006
2772Velcade plus KOS-953. Message 23091058Icebrg-12/11/2006
2771Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly Prolongs TiIcebrg-12/11/2006
2770Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) foIcebrg-12/11/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News